A liquid biopsy to detect circulating tumor DNA after surgery for stage 2 colon cancer reduces the use of chemotherapy without sacrificing recurrence-free survival.
CHICAGO — Circulating tumor DNA analysis safely reduced adjuvant chemotherapy use without compromising recurrence-free survival among patients with stage II colon cancer, according to results of the randomized phase 2 DYNAMIC trial.The findings, presented during ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine, showed patients with circulating tumor